L2B – Preclinical
Your external drug Research and developpement (R&D) Project Lead
in preclinical Oncology, Neuroscience & Neuro-oncology
Service eligible for the French government's tax credit “Credit d'Impot Recherche (CIR)”
​
I provide R&D project management to:
-
Develop and execute experimental and preclinical research plans, maximizing early-stage risk assessment.
-
Draft and optimize Target Product Profile (TPP) involving all stakeholders.
-
Design and conduct Proof of Concept (PoC) and Mechanism of Action (MoA) studies as expert pharmacologist.
-
Coordinate PK/PD & Tox studies & CMC as project manager.
-
Engage & manage CRO and academic partners engagement & management.
-
Review reports, audit raw data & interpret.
-
Punctual project audit, brainstorm or board seat.
-
Act as transition CSO for startups.
​
Recent project exemples:
-
Project lead - efficacy and administration route optimization to revive IP position (new formulation patent) of a lead.
-
Project coordinator: design clinical and preclinical Target Product Profile (TPP) of an oncology preclinical drug candidate.
-
Project lead - Draft and initiate the development plan from discovery to clinics (FIM) for a cancer specific targeting strategy at discovery stage.
-
Project manager - pharmacology report and IND submission review including identification and correction of flawed data.
​
My unique value resides in combining:
-
The Owls eye: in depth, detailed oriented, scientific analysis seeing trough shady, complex situation
-
The Chameleon 360° vision: long term global vision of drug development value chain able to incorporate information from different directions including IP & finance, market insights, and payers’ expectations
-
Dog’s heart: definitely patient’s benefit oriented and team player. I’m dedicated to incorporate complex and long term insights early on trough preclinical development and bring together key stakeholder to maximize your product value and its impact on patient’s health.
Our Clients Say
"Sandrine helped us set up a new project in preclinical oncology. Although we initially wondered about her international reach from the south of France, we were positively impressed by her ability to create value by leveraging an international network. Her main assets are her palpable enthusiasm and passion for science. She takes a genuine interest in projects and works exceptionally hard to move her customers' projects forward in a timely manner. She made several proactive suggestions that saved us time in CRO selection and study design, and was instrumental in shaping our Target Product Profile (TPP). The interaction was extremely positive and we recommend her highly."
Matthew Fyfe, Senior Vice President of Therapeutics at Storm Therapeutics, Cambridge, UK
Get in Touch
Let's discuss your needs.